iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: http://pubmed.ncbi.nlm.nih.gov/26841786/
A Round-Up on Cost-Effectiveness of Hypertension Therapy Based on the 2014 Guidelines - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Mar;18(3):24.
doi: 10.1007/s11886-016-0703-3.

A Round-Up on Cost-Effectiveness of Hypertension Therapy Based on the 2014 Guidelines

Priyanka Wani  1 , Carlos Blanco-Garcia  2
Affiliations
Review

A Round-Up on Cost-Effectiveness of Hypertension Therapy Based on the 2014 Guidelines

Priyanka Wani et al. Curr Cardiol Rep. 2016 Mar.

Abstract

Cardiovascular diseases are the leading cause of death in the USA. Moreover, hypertension affects approximately 78 million people in the USA and is a major modifiable risk factor. Therefore, elevated blood pressure is listed as the primary contributory cause of death in 15 % of the 2.4 million deaths in 2009. Nonetheless, 44 % of the hypertensive population in the USA did not have it under control in 2014. Hypertension cost was averaged to be 40-50 billion dollars yearly including medications and services and currently rising. New hypertension guidelines recommend treating individuals between ages 35 and 74 with different stages of hypertension. Furthermore, individuals with existing co-morbidities such as chronic kidney disease and diabetes should have increased medication adherence and different blood pressure goal compared to those without co-morbidities. Studies utilizing quality-adjusted life-years (QUALYs) were conducted to asses the cost-effectiveness of treating previously untreated adults with hypertension. On average, treating adults between ages 35 to 74 years could prevent about 50,000 and 13,000 cardiovascular events and deaths, respectively. Overall, treating stage 1 and 2 hypertension adults including emphasis on medication adherence could be effective and cost saving. The purpose of this article is to review different methods and assess cost-effectiveness for hypertension therapy based on the 2014 guidelines.

Keywords: Cardiovascular events; Cost-effective; Hypertension; QUALY.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Hypertens Res. 2008 Dec;31(12):2115-27 - PubMed
    1. MMWR Morb Mortal Wkly Rep. 2012 Sep 7;61:703-9 - PubMed
    1. PLoS Med. 2015 Aug 04;12(8):e1001860 - PubMed
    1. Hypertension. 2015 May;65(5):1041-6 - PubMed
    1. Hypertension. 2006 Jun;47(6):1039-48 - PubMed

MeSH terms

Substances

LinkOut - more resources